JP7539902B2 - グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用 - Google Patents

グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用 Download PDF

Info

Publication number
JP7539902B2
JP7539902B2 JP2021546056A JP2021546056A JP7539902B2 JP 7539902 B2 JP7539902 B2 JP 7539902B2 JP 2021546056 A JP2021546056 A JP 2021546056A JP 2021546056 A JP2021546056 A JP 2021546056A JP 7539902 B2 JP7539902 B2 JP 7539902B2
Authority
JP
Japan
Prior art keywords
glp1
gdf15
fusion protein
peptide
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021546056A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022513363A (ja
JP2022513363A5 (https=
Inventor
エム． ランキン，マシュー
リン－シュミット，シェファン
ファン，チチ
ファーマン，ジェニファー
ジェン，ソンマオ
ラングワラ，シャミナ
エム． ネルソン，セレーナ
マリカン，シャノン
Original Assignee
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー filed Critical ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー
Publication of JP2022513363A publication Critical patent/JP2022513363A/ja
Publication of JP2022513363A5 publication Critical patent/JP2022513363A5/ja
Priority to JP2024135217A priority Critical patent/JP2024170428A/ja
Application granted granted Critical
Publication of JP7539902B2 publication Critical patent/JP7539902B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021546056A 2018-10-22 2019-10-22 グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用 Active JP7539902B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024135217A JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862748603P 2018-10-22 2018-10-22
US62/748,603 2018-10-22
PCT/IB2019/059029 WO2020084496A1 (en) 2018-10-22 2019-10-22 Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024135217A Division JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用

Publications (3)

Publication Number Publication Date
JP2022513363A JP2022513363A (ja) 2022-02-07
JP2022513363A5 JP2022513363A5 (https=) 2022-10-27
JP7539902B2 true JP7539902B2 (ja) 2024-08-26

Family

ID=70330680

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021546056A Active JP7539902B2 (ja) 2018-10-22 2019-10-22 グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用
JP2024135217A Pending JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024135217A Pending JP2024170428A (ja) 2018-10-22 2024-08-14 グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用

Country Status (24)

Country Link
US (3) US11713345B2 (https=)
EP (2) EP4520343A3 (https=)
JP (2) JP7539902B2 (https=)
KR (1) KR20210081389A (https=)
CN (2) CN119751697A (https=)
AU (2) AU2019368816B2 (https=)
BR (1) BR112021007376A2 (https=)
CA (1) CA3116983A1 (https=)
CL (1) CL2021000987A1 (https=)
CO (1) CO2021005051A2 (https=)
CR (1) CR20210193A (https=)
DO (1) DOP2021000075A (https=)
EA (1) EA202191105A1 (https=)
EC (1) ECSP21028914A (https=)
ES (1) ES3011982T3 (https=)
IL (1) IL282297B1 (https=)
JO (1) JOP20210084A1 (https=)
MX (1) MX2021004665A (https=)
MY (1) MY205905A (https=)
PE (1) PE20211078A1 (https=)
PH (1) PH12021550885A1 (https=)
SA (1) SA521421825B1 (https=)
SG (1) SG11202103990QA (https=)
WO (1) WO2020084496A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10336812B2 (en) * 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
EP3883960A4 (en) * 2018-11-20 2022-11-09 Janssen Pharmaceutica NV GDF15 ANALOGUES AND METHODS OF USE TO REDUCE BODY WEIGHT AND/OR REDUCING FOOD INTAKE
WO2020185533A1 (en) * 2019-03-08 2020-09-17 Amgen Inc. Growth differentiation factor 15 combination therapy
EP4085077A4 (en) 2019-12-31 2024-01-17 Beijing QL Biopharmaceutical Co., Ltd. Fusion proteins of glp-1 and gdf15 and conjugates thereof
US11981718B2 (en) * 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
WO2022221291A2 (en) * 2021-04-12 2022-10-20 University Of Florida Research Foundation Incorporated Compositions and methods for treating obesity
CN117750968A (zh) * 2021-05-21 2024-03-22 株式会社柳韩洋行 用于预防或治疗非酒精性脂肪性肝病或非酒精性脂肪性肝炎的包括生长分化因子-15变体的组合物
CA3219645A1 (en) * 2021-05-21 2022-11-24 Yuhan Corporation Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases
CN120530128A (zh) * 2022-11-18 2025-08-22 株式会社柳韩洋行 双功能蛋白及其用途
CN116813742A (zh) * 2022-11-22 2023-09-29 杭州博茵生物技术有限公司 人gdf-15抗原表位肽、抗原、抗体、试剂盒及应用
WO2024144431A1 (ru) * 2022-12-29 2024-07-04 Авва Фармасьютикалс Лтд Новый штамм-продуцент escherichia coli, продуцирующий гибридный белок cbd-hs-es-glp1, и способ получения полипептида glp-1
JP2026505740A (ja) * 2023-01-20 2026-02-18 コリア アドバンスト インスティチュート オブ サイエンス アンド テクノロジー Ｇｆｒａｌを標的にするアンチセンスオリゴマー及びこの用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
US20080044411A1 (en) 2006-07-18 2008-02-21 O'neil Karyn T Human glp-1 mimetibodies, compositions, methods and uses
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
DK1641823T3 (da) 2003-06-12 2011-12-12 Lilly Co Eli GLP-1-analog fusionsproteiner
US20090099031A1 (en) 2005-09-27 2009-04-16 Stemmer Willem P Genetic package and uses thereof
WO2009142773A2 (en) * 2008-05-22 2009-11-26 Bristol-Myers Squibb Company Multivalent fibronectin based scaffold domain proteins
JP5444363B2 (ja) 2008-10-31 2014-03-19 セントビンセンツ ホスピタル シドニー リミテッド 慢性腎疾患における予後判定の方法
US9012719B2 (en) * 2009-02-06 2015-04-21 Syngenta Participations Ag Modification of multidomain enzyme for expression in plants
TW201101990A (en) 2009-07-08 2011-01-16 zhen-zheng Huang Plant media
KR20120097481A (ko) 2009-07-20 2012-09-04 내셔날 쳉쿵 유니버시티 사람 혈청 알부민(ＨＳＡ)의 변이체와 컨쥬게이션된 αｖβ3 인테그린에 대해 선택적인 폴리펩타이드 및 이의 약제학적 용도
WO2012091564A2 (en) * 2010-12-27 2012-07-05 Apo-T B.V. A cross-linking polypeptide that induces apoptosis
ES2666856T3 (es) 2011-11-04 2018-05-08 Novartis Ag Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
EP3683228A3 (en) 2012-01-26 2020-07-29 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
CA2862516C (en) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
MX361088B (es) * 2012-11-21 2018-11-26 Janssen Biotech Inc Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
ES2791183T3 (es) 2012-12-21 2020-11-03 Aveo Pharmaceuticals Inc Anticuerpos anti-GDF15
LT2948559T (lt) 2013-01-25 2018-06-25 Janssen Biotech, Inc. Kv1.3 antagonistai ir jų panaudojimo būdai
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
JP6475233B2 (ja) 2013-06-20 2019-02-27 ノヴォ ノルディスク アー／エス Ｇｌｐ−１誘導体及びその使用
US9862752B2 (en) 2013-07-31 2018-01-09 Amgen Inc. Growth differentiation factor 15 (GDF-15) constructs
GB201403794D0 (en) * 2014-03-04 2014-04-16 Univ Manchester Novel antimicrobial peptides
US10588980B2 (en) * 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
RU2017101436A (ru) 2014-06-24 2018-07-24 Ново Нордиск А/С Mic-1 слитные белки и их применение
AU2015296640B2 (en) 2014-07-30 2020-05-21 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
US10603359B2 (en) 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
EP3701969A1 (en) 2014-10-31 2020-09-02 NGM Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
GB201512733D0 (en) 2015-07-20 2015-08-26 Genagon Therapeutics Ab Therapeutic agents for treating conditions associated with elevated GDF15
JP6946304B2 (ja) 2015-12-22 2021-10-06 ノバルティス アーゲー 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法
CN108697795A (zh) * 2016-02-29 2018-10-23 伊莱利利公司 Gfral受体疗法
US10336812B2 (en) 2016-05-10 2019-07-02 Janssen Biotech, Inc. GDF15 fusion proteins and uses thereof
KR102433503B1 (ko) 2016-05-24 2022-08-18 노보 노르디스크 에이/에스 Mic-1 화합물 및 이것의 사용
KR20190059312A (ko) 2016-10-12 2019-05-30 얀센 바이오테크 인코포레이티드 Gdf15-유사 생물학적 활성의 조절제에 대한 스크리닝 방법
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
EA202191105A1 (ru) 2018-10-22 2021-08-03 Янссен Фармацевтика Нв Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
EP3883960A4 (en) 2018-11-20 2022-11-09 Janssen Pharmaceutica NV GDF15 ANALOGUES AND METHODS OF USE TO REDUCE BODY WEIGHT AND/OR REDUCING FOOD INTAKE

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
US20080044411A1 (en) 2006-07-18 2008-02-21 O'neil Karyn T Human glp-1 mimetibodies, compositions, methods and uses
WO2014120619A2 (en) 2013-01-30 2014-08-07 Ngm Biopharmaceuticals, Inc. Compositions and methods of use in treating metabolic disorders
US20170204149A1 (en) 2014-06-23 2017-07-20 Novartis Ag Hsa-gdf-15 fusion polypeptide and use thereof

Also Published As

Publication number Publication date
JP2024170428A (ja) 2024-12-10
ECSP21028914A (es) 2021-05-31
US20220089669A1 (en) 2022-03-24
JP2022513363A (ja) 2022-02-07
EP3870211A1 (en) 2021-09-01
DOP2021000075A (https=) 2021-12-15
IL282297B1 (en) 2026-04-01
KR20210081389A (ko) 2021-07-01
SG11202103990QA (en) 2021-05-28
CO2021005051A2 (es) 2021-04-30
CR20210193A (es) 2021-06-15
MY205905A (en) 2024-11-20
AU2019368816B2 (en) 2025-01-30
US11713345B2 (en) 2023-08-01
CN113226351A (zh) 2021-08-06
BR112021007376A2 (pt) 2021-08-10
EP3870211A4 (en) 2022-08-10
EA202191105A1 (ru) 2021-08-03
ES3011982T3 (en) 2025-04-08
WO2020084496A1 (en) 2020-04-30
MX2021004665A (es) 2021-08-24
US20250197468A1 (en) 2025-06-19
IL282297A (en) 2021-05-31
EP4520343A2 (en) 2025-03-12
CA3116983A1 (en) 2020-04-30
PH12021550885A1 (en) 2022-02-21
EP3870211B1 (en) 2025-01-08
SA521421825B1 (ar) 2024-03-06
AU2019368816A1 (en) 2021-05-13
EP4520343A3 (en) 2025-05-21
PE20211078A1 (es) 2021-06-09
AU2025203071A1 (en) 2025-05-22
US12275770B2 (en) 2025-04-15
US20230322888A1 (en) 2023-10-12
CN113226351B (zh) 2025-01-14
EP3870211C0 (en) 2025-01-08
CL2021000987A1 (es) 2021-09-10
CN119751697A (zh) 2025-04-04
JOP20210084A1 (ar) 2021-04-22

Similar Documents

Publication Publication Date Title
JP7539902B2 (ja) グルカゴン様ペプチド１（ｇｌｐ１）－増殖分化因子１５（ｇｄｆ１５）融合タンパク質及びその使用
KR102865076B1 (ko) 글루카곤-유사 펩티드 1(glp-1) 융합 펩티드 커플링된 사이클릭 펩티드 티로신 티로신 접합체 및 이의 용도
US20240117000A1 (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
HK40120308A (zh) 胰高血糖素样肽1(glp1)-生长分化因子15(gdf15)融合蛋白及其用途
HK40060006A (en) Glucagon like peptide 1 (glp1)-growth differentiation factor 15 (gdf15) fusion proteins and uses thereof
EA050724B1 (ru) Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение
HK40060006B (zh) 胰高血糖素样肽1(glp1)-生长分化因子15(gdf15)融合蛋白及其用途
HK40045710B (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
HK40045710A (en) Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20211227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221019

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221019

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231010

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240410

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240716

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240814

R150 Certificate of patent or registration of utility model

Ref document number: 7539902

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150